Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome



Status:Recruiting
Conditions:Ocular, Rheumatology
Therapuetic Areas:Ophthalmology, Rheumatology
Healthy:No
Age Range:18 - Any
Updated:3/8/2019
Start Date:June 30, 2017
End Date:June 30, 2019
Contact:Kim Williams
Email:kim.williams@lexitas.com
Phone:919-287-3395

Use our guide to learn which trials are right for you!

A Double-Masked, Randomized, Multi-Center Phase 2 Study to Evaluate the Efficacy and Safety of Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

The objective of this study is to evaluate the efficacy and safety of two strengths of
Lacripep™ ophthalmic solution versus placebo administered three times daily for four weeks in
subjects with a diagnosis of Dry Eye associated with documented Primary Sjögren's Syndrome

This is a multi-center, randomized, placebo-controlled, double-masked, parallel-group study.
Subjects will be randomized into three treatment groups: 0.005%, or 0.01% Lacripep™, or
placebo in a 1:1:1 ratio.

Inclusion Criteria:

Subjects who meet the following criteria will be selected:

1. Subjects who are age 18 years of age or older at the time of obtaining informed
consent.

2. Subjects with a documented prior history or current diagnosis of Primary Sjögren's
Syndrome according the American-European Consensus Group Sjögren's Syndrome Criteria
(Appendix 4; must meet either 4 out of 6 total criteria OR 3 out of 4 signs). Note:
Subjects who are on systemic (oral) therapy for the treatment of Sjögren's Syndrome
must be on stable systemic treatment defined as the same treatment for the immediately
prior 90 days.

3. Subjects with a history of dry eye-related ocular symptoms, and who have self-reported
use of over the counter ocular wetting agents within the last 120 days.

4. Subjects who meet the following criteria at both screening and Visit 2
(Randomization/Baseline) examinations:

1. FCS total score ≥ 4 and < 15 in the NEI/Industry Workshop scale, (Appendix 6)

2. Symptom Severity score of ≥ 40 using the SANDE questionnaire (Appendix 3)

3. Anesthetized Schirmer test score ≤ 5 mm wetting/5 min

4. LGCS total score ≥ 5 using the NEI/Industry Workshop scale (where 0=no staining)
Note: Subjects must meet all 4 criteria and eligible scores for FCS, Anesthetized
Schirmer and LGCS must be in at least one eye and it must be in the same eye at
the time of the visit.

Exclusion Criteria:

Subjects meeting any of the following criteria at the Visit 1 (Screening) or Visit 2
(Randomization/Baseline) visits will be excluded:

1. Subjects with any active infectious ocular condition.

2. Subjects who are monocular or have a BCVA, using corrective lenses if necessary, of
+1.0 logMAR or worse as assessed by Early Treatment Diabetic Retinopathy Study
(ETDRS).

3. Subjects with ocular inflammatory conditions (e.g., conjunctivitis, keratitis,
anterior blepharitis, etc.) not related to dry eye syndrome.

4. Subjects with clinical evidence of cicatricial ocular surface disease, such as
cicatricial ocular pemphigoid or Stevens Johnson syndrome.

5. Subjects who cannot suspend the use of any topical eye medications (including topical
cyclosporine) other than the investigational product during the run-in and the study
treatment phase.

6. Subjects who have used Restasis® (topical ophthalmic cyclosporine) or Xiidra® (topical
ophthalmic lifitegrast) within 14 days prior to Visit 1.

7. Subjects who in the study eye have fluorescein corneal staining (FCS) Total Score = 15
or a Score = 3 in the superior region per the NEI/Industry Workshop scale or subjects
who have FCS with diffuse confluent staining, filaments or frank epithelial defects.

8. Subjects who have active or have had an outbreak of herpetic keratitis within 365 days
of Visit 1 or subjects who are on chronic oral antivirals for ocular herpetic disease.

9. Subjects who cannot suspend the use of and abstain from contact lens use from the
Screening Visit (Visit 1) to the end of the study (Visit 5).

10. Subjects who have a history of collagen vascular disease, auto immune disease or
rheumatic disease other than Primary Sjögren's Syndrome (e.g., Lupus, Rheumatoid
Arthritis, etc.).

11. Subjects who have a history of or current Anterior Membrane Dystrophy.

12. Subjects who have had a corneal transplant or similar corneal surgery (DALK, DSEK,
DMEK, etc.).

13. Subjects who have used or anticipate use of amiodarone.

14. Subjects who within 30 days prior to Visit 1 alter the dose or anticipate alterations
to the dose of the following: tetracyclines, Omega 3's or 6's.

15. Subjects who within 60 days prior to Visit 1 and for the duration of the study alter
the dose or anticipate alterations to the dose of the following: anticholinergics,
antidepressants, oral contraceptives, isotretinoin, oral systemic corticosteroids,
oral systemic immunosuppressive agents.

16. Subjects who within 30 days prior to Visit 1 and for the duration of the study use
topical ocular antihistamines, ocular, inhaled or intranasal corticosteroids, topical
or oral mast cell stabilizers, oral antihistamines, topical or nasal vasoconstrictors,
topical ocular NSAIDs, topical ocular antibiotics or serum tears.

17. Subjects who in the study eye have had cauterization of the punctum or alterations to
(insertion or removal) punctal plug(s) within the past 14 days prior to Visit 1. Note:
If a punctal plug in place at Visit 2 (Randomization/Baseline) and it is dislodged,
the plug should be replaced as soon as possible.

18. Subjects who, in the study eye, have had corneal refractive surgery (LASIK, PRK, RK).

19. Subjects who in the study eye, have a history of any operative procedure on the ocular
surface or eyelids within 365 days prior to Visit 1 or with a history of intraocular
surgery within 90 days prior to Visit 1.

20. Subjects who are pregnant or suspected to be pregnant and subjects who are
breastfeeding or intend to breastfeed. Female subjects of childbearing potential are
required to have a negative urine pregnancy test at screening, and must agree to use
an acceptable method of contraception from the time of signing informed consent until
the end of study visit. Medically acceptable contraception methods include
intrauterine device; barrier methods such as diaphragm, condom, cap or sponge, used
with a spermicide; or hormonal contraception.

21. Subjects with any physical or mental impairment that would preclude participation and
the ability to give informed consent.

22. Subjects who have participated in a device or Investigational drug study or clinical
trial within 30 days of Visit 1. Participation in another during this study is
excluded for the duration of this study.
We found this trial at
30
sites
Saint Louis, Missouri 63131
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Azusa, California 91702
?
mi
from
Azusa, CA
Click here to add this to my saved trials
380 Minor Lane
Berkeley, California 94720
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
Birmingham, Alabama 35294
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Bloomington, Minnesota 55431
?
mi
from
Bloomington, MN
Click here to add this to my saved trials
Cleveland, Ohio 44115
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Delray Beach, Florida 33484
?
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Fargo, North Dakota 58103
?
mi
from
Fargo, ND
Click here to add this to my saved trials
Garden Grove, California 92843
?
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Glendale, California 91205
?
mi
from
Glendale, CA
Click here to add this to my saved trials
High Point, North Carolina 27262
?
mi
from
High Point, NC
Click here to add this to my saved trials
Hoffman Estates, Illinois
?
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
Indianapolis, Indiana 46290
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
7205 Bonneval Road
Jacksonville, Florida 32256
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Kansas City, Missouri 64111
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
?
mi
from
League City, TX
Click here to add this to my saved trials
?
mi
from
Littleton, CO
Click here to add this to my saved trials
Louisville, Kentucky 40206
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Norfolk, Virginia 23502
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Ormond Beach, Florida 32174
?
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rancho Cordova, California 95670
?
mi
from
Rancho Cordova, CA
Click here to add this to my saved trials
Rapid City, South Dakota 57701
?
mi
from
Rapid City, SD
Click here to add this to my saved trials
Roanoke, Virginia 24016
?
mi
from
Roanoke, VA
Click here to add this to my saved trials
8416 E. Shea Blvd., Ste C-101
Scottsdale, Arizona 85260
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Slingerlands, New York 12159
?
mi
from
Slingerlands, NY
Click here to add this to my saved trials
Tampa, Florida 33603
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Torrance, California 90505
?
mi
from
Torrance, CA
Click here to add this to my saved trials
Winchester, Massachusetts 01890
?
mi
from
Winchester, MA
Click here to add this to my saved trials